博来霉素应用于临床已超过18年。在睾丸癌,头颈癌、宫颈癌和淋巴肿瘤治疗中占重要地位。由于博来霉素可能产生蓄积性剂量限制性肺毒性,所以本药一般不长期应用于病人.最近报道的博来霉素新同类物 Lib-lomycin(LBM)具有较强抗肿瘤活性而未发现肺毒性。本文对 LBM 抗肿瘤活性、肺毒性及血液学毒性作了评述。 Bleomycin has been used clinically for more than 18 years. In testicular cancer, head and neck cancer, cervical cancer and lymphoma treatment occupies an important position. Because bleomycin may produce cumulative dose-limiting pulmonary toxicity, the drug is generally not long-term use in patients with recent reports of bleomycin novel congener Lib-lomycin (LBM) has strong antitumor activity was not found Pulmonary toxicity. This article reviews the anti-tumor activity, lung toxicity and hematological toxicity of LBM.